Haji-Allahverdipoor Kaveh, Eslami Habib, Rokhzadi Koosha, Jalali Javaran Mokhtar, Rashidi Monfared Sajad, Khademerfan Mohamad Bagher
Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medicinal Sciences, Bandar Abbas, Iran.
BioTechnologia (Pozn). 2024 Sep 30;105(3):201-213. doi: 10.5114/bta.2024.141801. eCollection 2024.
Recombinant plasminogen activator (r-PA) consists of the Kringle-2 and protease domains of human tissue-type plasminogen. It is used clinically to treat coronary artery thrombosis and acute myocardial infarction. However, the expression and production of reteplase (r-PA) are limited due to its susceptibility to proteolysis during manufacturing processes. Therefore, efforts have been made to address this limitation.
To enhance the conformational stability of r-PA and increase its resistance to proteolysis, we used Gly 6 Ala substitutions in the Kringle-2 domain through . We created an mutant collection with eight structures, incorporating four designated mutations (R103S, G39A, G53A, and G55A). Using MODELLER software and homology modeling, we developed three-dimensional structures for two Kringle-2 and tissue plasminogen activator protease domains, including the wild noncleavable form (R103S) and mutants with all four designated mutations. We assessed protein stability using a dynamic cross-correlation matrix by extracting global properties such as Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) from trajectory files.
The findings revealed that a single glycine-alanine substitution (G39A) enhanced the conformational stability of r-PA, as evidenced by improvements in RMSD, RMSF, radius of gyration, surface accessibility, hydrogen bond formation, eigenvector projection, and density analysis.
The conformational stability of r-PA conferred by glycine replacement with alanine may decrease the propensity for proteolysis in protease - rich environments across various recombinant systems and potentially enhance its production and expression levels.
重组纤溶酶原激活剂(r-PA)由人组织型纤溶酶原的kringle-2和蛋白酶结构域组成。它在临床上用于治疗冠状动脉血栓形成和急性心肌梗死。然而,瑞替普酶(r-PA)在制造过程中由于易受蛋白水解作用,其表达和产量受到限制。因此,人们一直在努力解决这一限制。
为提高r-PA的构象稳定性并增加其对蛋白水解的抗性,我们通过[具体方法]在kringle-2结构域中进行了甘氨酸到丙氨酸的替换。我们创建了一个具有八种结构的突变体文库,包含四个指定突变(R103S、G39A、G53A和G55A)。使用MODELLER软件和同源建模,我们为两个kringle-2和组织纤溶酶原激活剂蛋白酶结构域开发了三维结构,包括野生型不可切割形式(R103S)和具有所有四个指定突变的突变体。我们通过从轨迹文件中提取诸如均方根偏差(RMSD)和均方根波动(RMSF)等全局特性,使用动态交叉相关矩阵评估蛋白质稳定性。
研究结果表明,单个甘氨酸-丙氨酸替换(G39A)增强了r-PA的构象稳定性,RMSD、RMSF、回转半径、表面可及性、氢键形成、特征向量投影和密度分析的改善证明了这一点。
用丙氨酸替代甘氨酸赋予r-PA的构象稳定性可能会降低其在各种重组系统中富含蛋白酶的环境中被蛋白水解的倾向,并有可能提高其生产和表达水平。